Search
Tazemetostat
go.drugbank.com/drugs/DB12887ApprovedInvestigational[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]
Lexibulin
go.drugbank.com/drugs/DB05147InvestigationalCYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias
Iodine
go.drugbank.com/drugs/DB05382ApprovedInvestigationalIodine is commonly used as an antiseptic for minor cuts and abrasions, preventing infections that may result from contaminated wounds.
Norethynodrel
go.drugbank.com/drugs/DB09371ApprovedAs a contraceptive, it has usually been administered in combination with MESTRANOL.
Enzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.
Dexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalDexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002 . It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant . It is used for treatment of Attention Deficit Hyperactivity Disord...
19-norandrostenedione
go.drugbank.com/drugs/DB01434ExperimentalIllicitAfter 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. … In the body 19-norandrostenedione is rapidly metabolized into [nandrolone], also known as nortestosterone.
Manidipine
go.drugbank.com/drugs/DB09238ApprovedInvestigationalWithdrawnManidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive.
Neostigmine
go.drugbank.com/drugs/DB01400ApprovedInvestigationalVet approvedA cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine.
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.